In The News

CEOCFO Magazine 2016 Interview with John M. Burke, PhD

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath, discusses advanced mathematical dynamical systems pharmacology modeling and biology applications for drug discovery, development and clinical trials. "Our mathematical and biological rigor allows us to provide deep biological insights years earlier than they would surface in the clinic," said Dr. John M. Burke. "This is what sets us apart from previous efforts and also from competitors."

Dr. John Burke featured in CEO/CFO Magazine

Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, LLC was recently featuerd in CEO/CFO magazine. Lynn Fosse, Senior Editor of CEOCFO Magazine interviewed Dr. Burke to learn about how Applied BioMath is revolutionizing drug invention, why its technology is different than anything offered today, and examples where Applied BioMath helped optimize and accelerate drug development.

Read Dr. Burke's interview in CEO/CFO Magazine

Applied BioMath, LLC to sponsor and moderate at Cancer Advance Boston 2016

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug development, today announced that they will sponsor, moderate, and participate in Cancer Advance Boston 2016.    Cancer Advance, being held April 4-5 at Harvard Medical School, brings together distinguished cancer experts from academia and industry, alongside the people who help turn discoveries into therapies for a high-energy, uniquely interactive meeting focused on the latest in cancer research. 

Applied BioMath holds its full-day Science and Strategy Meeting

Applied BioMath's Scientific and Executive Leadership Teams recently spent the day at our Science and Strategy offsite. We reflected on 2015 projects, shared new science and technologies, and officially kicked off 2016. We are extremely proud of what we achieved in 2015, and we will work diligently to continue that momentum into and throughout 2016!

Applied BioMath welcomes Werner Meier to its Scientific Advisory Board

Applied BioMath ( is thrilled to announce that Werner Meier is the newest member of its Scientific Advisory Board, which comprises pioneers and thought leaders in the mathematical modeling, biological engineering, biotechnology, and medical fields.   Werner joins key opinion leaders Douglas Lauffenburger, PhD, Dr. Joseph Loscalzo, MD, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD. 

Applied BioMath, LLC announces collaboration with Zymeworks Inc.

Applied BioMath, LLC ( today announced a collaboration with Zymeworks Inc. (, a leader in the development of bi-specific antibodies, to leverage Applied BioMath's proprietary analytical and predictive capabilities in quantitative systems pharmacology.   

Applied BioMath announces annual Charitable Giving Program

At Applied BioMath, we believe strongly in giving back to our community.  One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team.

Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board

Applied BioMath is thrilled to announce that Dr.Joseph Loscalzo, MD, PhD is the newest member if its Scientific Advisory Board. Dr. Loscalzo is chair of the Department of Medicine and physician-in-chief at Brigham and Women's Hospital (BWH). A cardiovascular medicine specialist, he is also the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS). 

Applied BioMath, LLC. To Sponsor and Present at the Inaugural Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015

Applied BioMath, a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will sponsor and present at the Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015 on September 23-24 in Boston, MA.  Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present “QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials” on Thursday September 24, 2015 at 12:10 PM. 

Applied BioMath presents at "Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development"

John M. Burke, PhD President, CEO and Co-founder of Applied BioMath will present a talk on "Quantitative Systems Approaches in Inflammation to Enable Decision Making in Early Discovery and Clinical Trials" at the "Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development" conference on May 26, 2015 at the New York Academy of Sciences.